Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2020.07.01
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
PDF (155 KB)
2020.05.29
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastati ...
PDF (246 KB)
2020.05.29
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung ...
PDF (184 KB)
2020.05.29
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung ...
PDF (184 KB)
2020.05.29
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorect ...
PDF (180 KB)
2020.05.29
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KE ...
PDF (189 KB)
2020.05.28
Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC ...
PDF (231 KB)
2020.05.25
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastati ...
PDF (256 KB)
2020.05.22
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Can ...
PDF (139 KB)
2020.05.21
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
PDF (186 KB)
Showing 1 - 10 of 32 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...